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ABSTRACT
Diabetic foot ulcers (DFU) are chronic complications due to 
poor diabetic control. Diabetic foot ulcers can lead to lifelong 
disability and substantially diminish the quality of life. The aim 
of this study was to carry out a thorough evaluation of diabetic 
foot ulcer management, compare current scenario of DFUs care 
with the International guidelines and to identify the extended 
roles of clinical pharmacist to improve the conditions of diabetic 
patient with foot ulcers.
It is a retrospective qualitative study carried out in two 
tertiary care hospitals of Tamil Nadu state. The patients were 
selected based on inclusion and exclusion criteria admitted 
in the hospitals with diabetic foot ulcers. The patient’s socio-
demographic and clinical characteristics tools from the patient 
medication records (PMR) were collected and taken into 
considerations for the study.
The study revealed that diabetic foot ulcer was more prevalent 
among male patients with type 2 diabetes since 11 to 25 yrs 
belongs to the age group between 51-60 years. It was found that 
60.5% of the patients having at least one co-morbid condition 
and 90.6% of patients possess one or more risk factors to 
develop diabetic foot ulcers. Glycated hemoglobin (HbA1c) test 
were done only by 54.7% of the patients, which showed that it 
was not insisted as an important identification tool for diabetic 
foot ulcer. The PMR revealed numerous antibiotics switch-over 
for the wound treatment as well.
From the study it was concluded that an immediate requirement 
and thorough evaluation of enhanced foot care management, 
patient centered care and diabetic foot surveillance etc is 
needed for diabetic foot ulcer management. A comparative 
current scenario of DFUs care with the International guidelines 
and its adaptation and modifications according to our need is 
to be emphasized. Amalgamation of clinical pharmacy services 
with the multidisciplinary diabetic foot care team services is 
to be made. The clinical pharmacist’s intervention is to be put 
forward to improve the conditions of diabetic patient with foot 
ulcers to decrease the alarming incidences in Indian hospital 
settings.
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INTRODUCTION
Diabetes is a group of heterogeneous disorders characterized 
by hyperglycemia and glucose intolerance due to insulin 
deficiency, impaired effectiveness of insulin action, or 
both [1]. About 15%-25% of diabetic patients will develop 
chronic ulcers of foot or lower extremity during their 
lifetime [2-4].The etiology of foot ulcers is multi-factorial 
[3,5] among which peripheral vascular disease, neuropathy 
and retinopathy are considered to be the most important 
causative factors [6]. Foot ulcers in diabetic patient are the 
major sufferings and cost-effective [7]. Diabetic foot ulcer 
patients use more in and outpatient health resources and 
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this condition is one of the main factors for the hospital 
admission of diabetic patients [8].
In India incidence of foot ulcers vary by many socio-cultural 
practices which include barefoot walking, inadequate 
facilities for diabetic care, low levels of education and poor 
socio-economic conditions [9]. HbA1C measurements are 
used to test metabolic control in diabetics at least three 
months, and to assess the risk for complications [10]. 
Diabetic foot ulcer (DFU) can lead to lifelong disability and 
may substantially diminish the quality of life in these patients 
and only two third of these ulcers are expected to heal [11-
14]. The median time taken for the healing of these ulcers is 
approximately 6 months; up to 28% may result in some form 
of amputation [15] and the amputee patient’s life expectancy 
was found to be 4.32 years in a study [16].
If the treatment provided is inadequate that may result in 
therapeutic complications and unnecessary extension of 
healing times [17]. A variety of antibiotics ranging from 
narrow spectrum oral agents to broad spectrum parenteral 
agents are employed in treating diabetic foot infections. 
During the recent two decades study there are only a few 
investigations on antimicrobial therapy defined for the 
infections [18]. Studies on cost effectiveness of antimicrobials 
are very limited. The Infectious Society of India (IDSA) 
guideline recommends deep tissue culture study obtained 
by biopsy or curettage as study specimen and also suggest 
avoiding swab specimens, especially from inadequately 
debrided wounds, as they provide less accurate results.
Foot ulcers are susceptible to infection and poly-microbial 
infection which may spread rapidly, causing overwhelming 
tissue destruction. This process is the main reason for 
major amputation in neuropathic feet. Potential strategies to 
minimize the sequelae of foot complications includes early 
recognition of the ‘at risk’ foot; prompt use of preventative 
measures; and rapid and intensive treatment of foot 
complications in multidisciplinary foot care services [19-21]. 
Diabetic foot care guidelines considered to be one of the most 
cost-effective forms of health care expenditures provided 
that the guideline is goal-focused and properly implemented. 
International Diabetes Federation (IDF), Diabetes Atlas 
7thedition states that many governments and public health 
planners are still remain unaware of the current magnitude 
and more importantly the future potential increase of 
diabetes cases as well as its serious complication in their own 
countries. National Institute of Clinical Excellence (NICE) 
guideline insists patient centered care for foot ulcers with 
type1 and type 2 diabetes patients, where treatment and care 
should be taken into account according to the individual 
needs and preferences. Diabetic foot ulcer management 
centers have documented reductions in amputation rates up 
to 50% after coordinating the multidisciplinary efforts and 
incorporation of evidence-based wound care managements 
[22-28].
Aim
The aim of the study was to carry out a thorough evaluation 
of current DFU management, compare with international 
guidelines and to identify clearly the extended roles of the 
Clinical Pharmacist in the management and prevention of 
DFU.
Objective
•	 To	 identify	 current	 diabetic	 foot	 ulcer	 treatment	 and	
management modalities.
•	 To	 identify	 and	 compare	 essential	 domains	 in	 the	DFU	
management and prevention.
•	 To	 identify	 the	 extended	 responsibilities	 of	 clinical	 and	
community pharmacy services.
•	 To	 emphasize	 and	 discuss	 on	 the	 implementation	 of	 an	
effective prevention programme and standard practice.
Research design
Sample Setting
The retrospective qualitative study based on grounded 
theory method was conducted in two different tertiary care 
hospitals in Coimbatore and Chennai located in South India. 
The study was carried out at two different time periods 
for a total of 10 months. All procedures performed in the 
study were in accordance with the ethical standards of the 
institution and the study required no any formal consent.
Patient selection criteria
The two different study periods were taken, from March 2013 
to September 2013 and from December 2015 to February 
2016 respectively. and no any patients were repeated in the 
study. Type1 or type 2 diabetes mellitus patients of any age 
group, diagnosed with diabetic foot ulcers under medication 
with the prescribed antibiotics and who fulfilled the inclusion 
criteria, a total of 97 patients were recruited randomly from 
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inpatient wards from various departments of the tertiary 
care hospital. The highest numbers of diabetic foot ulcer 
patients were found in both male and female surgical wards. 
86 patients were included in the study and remaining 
11 patients were excluded from the study based on the 
inclusion-exclusion criteria. Exclusion criteria involve non-
diabetic patients, patients with cellulitic foot ulcer, diabetic 
patients with varicosities, patient with vasculitic ulcerations 
and lower extremity rashes.
Study design and methodology
This study was carried out in three phases.
Phase-I comprises review of Diabetes and Diabetic foot Ulcer 
Guidelines of National Institute of Clinical Excellence, UK; 
National Diabetes Education Program, USA and Infectious 
Diseases Society of America. A new patient documentation 
form was developed based on the requirement of these 
guidelines for the diabetic foot ulcer management.
Phase-II includes recruiting of patients under inclusion-
exclusion criteria based on the standard ethics. Patient 
documentation form (PDF) was designed, developed and 
tailored according to the study requirement based on the 
“Diabetes Care Program of Nova Scotia, Canada; National 
Diabetes Education Program, USA; Association of Wound 
Care and The National Institute of Clinical Excellence, UK” 
guidelines. Socio-demographic details of the selected patients 
were entered in the developed patient documentation form 
(PDF).
Phase-III involves the collection of patient’s variable factors 
like age, gender, diabetes type, duration of diabetic illness, 
risk factors, co-morbidities, culture test, antibiotics, length of 
stay, HbA1c level, fasting blood sugar, random blood sugar 
value etc taken into consideration for the study were grouped, 
analyzed and discussed.
Data Assessment and Management
The details obtained were brought under the domains like 
"Structured Foot Surveillance, Assessment of Risk Factors, 
Treatment and Management for ulcer and Prevention 
Measures" which were indicated by NICE guidelines as the 
requirements for diabetic foot ulcer management in hospital 
settings. For a descriptive analysis, basic statistical characters 
like mean, percentage and ± standard deviation were used.
Results
The study analyzed the selected 86 patients from PMR based 
on the classifications of gender, age, type and duration of 
diabetes, co-morbid conditions, risk factors, culture test, and 
HbA1c test and length of stay in hospital. The results of the 
basic socio-demographic and clinical characteristics of the 
patients were summarised in Table 1.
Table 1: Basic socio-demographic and clinical characteristics 
of the patients
Characteristics N=86 %
Sex
Men 59 68.6
Women 27 31.4
DM Type
Type 1 DM 3 3.5
Type 2 DM 83 96.5
Co-morbid conditions
Patients with 52 60.5
Patients without* 34 39.5
Risk factors
Patients with 78 90.6
Patients with out 4 4.7
Information N/A 4 4.7
Glycated Haemoglobin
HbA1c Test
Performed 47 54.7
Not performed 39 45.3
Culture test
Performed 51 59.3
Not performed 35 40.7
Isolated organism#(N = 51)
Single 20 39.2
Mixed 31 60.8
From the total sample size of 86 patients, men were around 
68.6% and 31.4% were women among the admitted patients. 
Most of the patients (96.5%) admitted were type2 diabetes. 
The patients around 60.5% were recorded to be having at 
least one co-morbid condition like high blood pressure, 
dyslipidemia and renal failure. The glycated haemoglobin 
test was performed with only 47 patients (54.7%). Culture 
test was done in 51 patients (59.3%) and among them single 
organism was isolated in 20 patients and mixed organisms 
were isolated in 31 patients. From the blood sample analysis 
for the selected patients, it was found that the HbA1c test 
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was done only of the patients. Among the study population 
about 90.6% were identified to have one or more risk factors 
Table 2, were likely to develop DFU. Poor glycemic control 
(44.18%) and diabetes for more than 10 years (30.2%) 
reported possesses the high risks of diabetic foot ulcers 
followed by history of previous amputation (25.6%), diabetic 
nephropathy (16.2%) and past foot ulcer history (11.6%).
Table 2: Risk factors
S. No List of Risk Factors$ No of Patients*
%
N=86
1 Diabetes for ≥ 10 years 38 44.18
2 Past Foot Ulcer History 26 30.23
3 Previous Amputation 22 25.58
4 Peripheral Neuropathy 14 16.27
5 Peripheral Vascular Disease 10 11.62
6 Poor Glycemic Control 51 59.30
7 Visual Impairment 19 22.09
8 Diabetic Nephropathy 26 30.23
9 Nicotine/ Cigarette Smoking 17 19.76
$ -On the basis of patient record
*-Patient’s every single risk factor is recorded under each category
Clinical characteristics of patients correlating with the 
development of DFU like age wise distribution, duration of 
diabetes and the length of stay in the hospital was categorized 
and summarized in Table 3. DFU incidences based on the 
age wise analysis revealed that the age between 51-60 years 
(39.5% of mean age 55.68) were found to be the more 
vulnerable to develop DFU followed by 61-70 years (31.4%) 
and 41-50 years (16.3%). There were patients having DFU 
each, one case from below 30 years and one above 80 years. 
The patients around 46.16% who developed DFU were 
found to have diabetes, duration 11-25 years. Unfortunately 
information on duration of diabetics were missing for 21 
(24.4%) of the patients. Patients stay in the hospital was less 
than a week to a month and a half. Information on frequency 
of admissions of the same patients or who had visited other 
clinics was lacking. Patients stayed less than a week were 
more in numbers and their average stay was found to be 5.03 
days.
Table 3: Clinical characteristics of patient with diabetic 
ulceration
Characteristics N=86 % Mean ± SD
Age wise distribution (yrs)
≤ 30 1 1.16 NA**
31-40 3 3.49 35.33±2.52
41-50 14 16.28 44.3±3.36
51-60 34 39.54 55.68±2.86
61-70 27 31.39 65.33±2.91
71-80 6 6.98 72.83±2.48
81-90 1 1.16 NA
Duration of Diabetes in yrs
(n=65)
≤1 6 9.23 09±2.37*
2-5 15 23.07 03.53±1.06
6-10 14 21.54 08.29±1.38
11-25 30 46.16 16.87±5.07
Length of stay in days
≤7 33 38.37 05.03±1.53
8-14 29 33.73 11.14±1.94
15-21 13 15.12 17.54±1.85
22-28 7 8.14 25.00±2.16
29-35 2 2.32 32.50±2.12
36-42 2 2.32 39.50±2.12
*value in month
**NA-not applicable
DISCUSSION
Risk of poorly controlled glycaemia had a high impact on 
the development of diabetic foot ulcers. Peripheral vascular 
disease, diabetic retinopathy and nicotine/cigarette smoking 
were also considerably found to be important while assessing 
the risk factors which can worsen the condition of diabetic 
foot ulcers. Previous studies had proved that there was a 
positive correlation between the treatment failures and the 
presence of risk factors. The available data for understanding 
the management of DFU and complications in the local 
hospital settings required to be improvised. The patient’s 
past medical history records can be modified with more 
relevant information. Treating the DFU patients under 
standardized practices would be more appropriate adopting 
the International DFU care to bring positive outcomes. 
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Comparison of the important domains for the effective 
management and prevention of DFU had been shown in 
Table 4. HbA1c was not done to the whole patients; reason 
being the cost factor, can be made cheaper and lack of 
guidelines insisting HbA1C is a mandatory diagnostic test for 
DFU was observed. Co-morbidities seen in DFU patients can 
be advised that it would worsen their health and it was found 
that an increased number of medicines were consumed by 
the patient.
Table 4: Study report on comparison of domains
Domain/ Areas* International
Guideline
Current care Possibility of 
Implementation
Guideline √ X Yes
Structured Education √ X Yes
Care planning √ No specific 
plan
Yes
Patient centred care √ X Yes
Annual structured 
foot surveillance
√ X Yes
Referral and 
management
√ X Yes
Multi disciplinary 
diabetic foot care 
Team
√ X Yes
Enhanced Foot Care 
Education
√ X Yes
* listed by the NICE guidelines
IDSA insists on deep tissue culture instead of swab or pus 
culture in order to obtain the accurate existence of micro-
organism. Though the list of isolated organisms was prepared 
on culture test yet the concordance with deep tissue culture 
and swab or pus culture must be ascertained. Treating DFU 
patients with the appropriate antibiotic regimen is crucial 
for the successful outcome and also to prevent antibiotic 
resistance which can ultimately reduce antibiotics switch-over 
events. IDSA has drawn guidelines for appropriate antibiotic 
regimen for the prophylaxis and treatment for classified DFU 
patients. Awareness, screening and surveillance programs 
can be organized at the hospitals centres, which could bring 
positive outcome in the society especially in India, where 
the diabetic population is expected to increase. Clinical 
Pharmacist intervention can be incorporated in rational use 
of antibiotics, risk assessment, antibiotic policy framing, 
organising awareness and preventive programs and other 
roles etc. which are listed below.
Roles of Clinical Pharmacist postulated in the 
management of diabetic foot ulcer care
 Develop, evaluate and document pharmaceutical care 
practices in DFU.
 Collaborate with other health care professionals to develop 
treatment guidelines for DFU.
 Educate all health professionals who participate in 
pharmaceutical care.
 Participate in health screening for diabetes, and DFU 
(HbA1c, FBS, PPBS, etc.).
 Conducting health promotion and education programs 
for smoking cessation, obesity control, DFU self-practice; 
DFU preventive measures DFU awareness camp etc.
 Educate and collaborate community pharmacist and their 
services in the prevention and
management of DFU.
 Referral for management from counseling centers and 
community pharmacies.
 Research in the field of pharmacotherapeutics; 
pharmacoepidemiology; pharmacy practice; health 
economics in diabetes and DFU.
 To evaluate and document the results of research in order 
to improve all aspects of pharmaceutical care.
 Participate in the formulation of antibiotic policy and its 
regulations
 Develop professional standards and audit procedures.
Limitations of the study
In this retrospective study some of the patient’s medical and 
medications history entry were not made available PMR. 
The study was carried out with 86 diabetic patients among 
whom only 3 patients were having type1 diabetes but more or 
equal numbers of type1 diabetes patients have to be recruited 
to confirm whether type 2 diabetes patients are also more 
vulnerable to develop DFU than type 1 diabetes.
Conclusion
An audit must be performed to identify high risk patients 
of diabetic foot ulcers and suitable preventive programmes 
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can be introduced as per the guidelines. Annual surveillance 
for all diabetic foot ulcer patients must be conducted in 
the hospital by the foot care team (podiatrist) organised 
in the hospital for the management and prevention from 
prognosis which is highly emphasised by the guidelines. 
The clinical pharmacist should make an attempt to develop 
treatment guidelines in collaboration with other health care 
professionals. A unique system of classifying diabetic foot 
infections suggested by the guidelines must be followed in 
the hospital setup for the optimal use of antibiotics. In order 
to identify accurate organism deep tissue culture rather 
than pus and swab culture tests could be adopted by the 
hospitals. Antibiotic guidelines for treating DFU/DFI and 
recommendation for the same must be brought for both 
empirical and for the treatment of infections. Initiation of 
the multidisciplinary team and implementation of clinical 
pharmacy services in the areas of antibiotic policies and 
guidelines framing, surveillance for high and low risk 
patients, and in organising awareness and preventive 
programs are important for the positive treatment outcome 
among DFU patients. It can be concluded that it is necessary 
to classify the DFU patients under anyone of the standard 
classifying system to assess the risk factors based on which 
preventive strategies can be drawn.
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Diyabetik Ayak Ülseri Tedavisi Üzerine Geçmişe Yönelik, 
Nicel Bir Çalışma ve Klinik Eczacının Artan Rolünün 
Tartışılması 
ÖZ
Diyabetik ayak ülseri (DFU), diyabetin yetersiz kontrolü 
sonucunda gelişen kronik bir komplikasyondur. DFU, hastanın 
ayağını zorlukla kullanmasına neden olduğu için yaşam 
kalitesini de düşürmektedir. Bu çalışmanın amacı, DFU’nin 
kontrolü ve tedavisi konusunda kapsamlı bilgi vermek, 
uluslararası kılavuzlarda yer alan DFU tedavisi ve bakımı 
konusundaki verileri karşılaştırmak, ve ayaklarında ülser 
gelişmiş diyabetli hastaların durumlarının iyileştirilmesinde 
klinik eczacının gün geçtikçe artan rolünü ifade etmektir. Bu 
çalışma, Tamil Nadu’da bulunan ve üçüncü basamak sağlık 
hizmeti veren iki hastanede yürütülmüş olan geçmişe yönelik 
ve nitel bir çalışmadır.Çalışmaya katılacak hastalar, DFU 
nedeniyle hastaneye başvuran hastalar arasından dahil etme 
ve dışarıda bırakma kriterleri göz önünde bulundurularak 
seçilmiştir. Hastalara ait sosyodemografik ve klinik veriler hasta 
kayıtlarından (PMR) toplanmıştır.
Bu çalışma, DFU’nin, 11-25 yıldır tip-2 diyabet tanısı ile 
yaşayan 51-60 yaş aralığındaki erkek hastalarda karşılaştırılan 
diğer hasta gruplarına kıyasla daha fazla görüldüğünü ortaya 
çıkartmıştır. Hastalardan %60.5’nin en az bir ko-morbid durum 
yaşadığı, hastaların %90.6’sının ise DFU gelişimi açısından 
bir ya da daha fazla risk faktörü taşıdığı tespit edilmiştir. 
Glikozillenmiş hemoglobin (HbA1c) testinin hastaların yalnızca 
%54.7’sine uygulandığı ve bu testin DFU’nin tanısı için üzerinde 
ısrarla durulan bir test olmadığı görülmüştür. Ayrıca, hasta 
kayıtlarından elde edinilen verilerde hastalara yara iyileşmesi 
için çok sayıda antibiyotik reçete edildiği saptanmıştır.
Bu çalışmada, DFU tedavisi ve bakımının acil bir gereklilik 
olduğu, DFU bakımı için hasta odaklı bir yaklaşım geliştirilmesi 
ve diyabetik ayak tarması yapılması gerektiği belirlenmiştir. 
Uluslararası kılavuzlarda bildirilen DFU tedavisi ve bakımının 
ülkemizdeki ihtiyaçlar göz önüne alınarak uyarlanması ve 
geliştirilmesi gereklidir.Klinik eczacılık hizmetleri ile çok 
disiplinli diyabetik ayak bakımı hizmetleri birleştirilmelidir. 
DFU’li hastaların yaşam kalitesinin arttırılması için klinik 
eczacıların sürece mutlaka katkıda bulunmasının Hindistan’da 
DFU nedeniyle hastanelere yapılan giderek artan sayıdaki 
başvuruyu önleyeceği düşünülmektedir.
Anahtar Kelimeler: Diyabet, diyabetik ayak ülseri (DFU), 
yaralar, kılavuzlar, klinik eczacılık hizmetleri.
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